Related Experiment Video
Updated: Jun 10, 2026
09:57
Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Experience with rufinamide in a pediatric population: a single center's experience
Martina Vendrame1, Tobias Loddenkemper, Vasu D Gooty
1Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
Pediatric Neurology
|August 10, 2010
Summary
Rufinamide shows efficacy and good tolerability in patients with refractory epilepsy. This antiepileptic drug is effective across various seizure types and epilepsy syndromes, including those beyond Lennox-Gastaut syndrome.
Area of Science:
- Neurology
- Pharmacology
- Epileptology
Background:
- Rufinamide is an antiepileptic drug approved for Lennox-Gastaut syndrome.
- Refractory epilepsy presents significant treatment challenges.
Purpose of the Study:
- To evaluate the efficacy, tolerability, safety, and dosing of rufinamide in patients with refractory epilepsy.
- To explore rufinamide's effectiveness in epilepsy syndromes beyond Lennox-Gastaut.
Main Methods:
- Retrospective analysis of 77 patients with refractory epilepsy treated with rufinamide.
- Assessment of seizure response rates, tolerability, and adverse events.
Main Results:
- Rufinamide demonstrated efficacy across diverse epilepsy syndromes, notably in focal cryptogenic epilepsies (81.1% response).
- Highest responder rates were observed in tonic/atonic (48.6%) and partial seizures (46.7%).
- Rufinamide was well tolerated, with only 13% of patients discontinuing due to side effects.
Conclusions:
- Rufinamide exhibits good efficacy and tolerability in refractory epilepsy.
- Its therapeutic potential may extend to various partial and generalized epilepsy syndromes.
- Rufinamide represents a valuable option for managing difficult-to-treat epilepsy.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...